GSGTF (Gensight Biologics) Research & Development: $7.47 Mil (TTM As of Dec. 2025)


What is Gensight Biologics Research & Development?

Gensight Biologics GSGTF Research & Development is $7.47 Mil as of Dec. 2025. The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Gensight Biologics's Research & Development for the six months ended in Dec. 2025 was $2.52 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $7.47 Mil.

Gensight Biologics  (OTCPK:GSGTF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Gensight Biologics Research & Development Related Terms

Gensight Biologics Research & Development Historical Data

* Premium members only.

The historical data trend for Gensight Biologics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gensight Biologics Research & Development Chart

Gensight Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.49 20.49 21.11 12.95 7.54

Gensight Biologics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.04 6.77 6.37 4.94 2.52

Gensight Biologics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $7.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $7.47 Mil mean?
Gensight Biologics (GSGTF) has a Research & Development of $7.47 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Gensight Biologics and its competitors.
Is Gensight Biologics' Research & Development too high?
Gensight Biologics' current Research & Development is $7.47 Mil.
How does Gensight Biologics' Research & Development compare to VRTX and REGN?
Gensight Biologics' Research & Development of $7.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Gensight Biologics and its competitors. Gensight Biologics's current Research & Development is $7.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (GSGTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.04, compared to a current price of $0.09 — trading 125% above its estimated fair value. The current Research & Development is $7.47 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Gensight Biologics (GSGTF), the current Research & Development is $7.47 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gensight Biologics Business Description

Address 74, rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.